EP Patent

EP1595539A4 — Drug for reducing side effects in ribavirin interferon combination therapy

Assigned to Mochida Pharmaceutical Co Ltd · Expires 2007-04-11 · 19y expired

What this patent protects

It is intended to provide a drug for reducing side effects (in particular, anemia) in ribavirin interferon combination therapy for hepatitis C which contains, as the active ingredient, at least one member selected from the group consisting of eicosapentaenoic acid (EPA) and pharm…

USPTO Abstract

It is intended to provide a drug for reducing side effects (in particular, anemia) in ribavirin interferon combination therapy for hepatitis C which contains, as the active ingredient, at least one member selected from the group consisting of eicosapentaenoic acid (EPA) and pharmaceutically acceptable salts and esters thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1595539A4
Jurisdiction
EP
Classification
—
Expires
2007-04-11
Drug substance claim
No
Drug product claim
No
Assignee
Mochida Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.